- Home
- CLMT vs PHVS Comparison
CLMT vs PHVS Comparison
Compare CLMT & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLMT
- PHVS
- Stock Information
- Founded
- CLMT 1916
- PHVS 2015
- Country
- CLMT United States
- PHVS Switzerland
- Employees
- CLMT N/A
- PHVS N/A
- Industry
- CLMT Oil & Gas Production
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- CLMT Energy
- PHVS Health Care
- Exchange
- CLMT Nasdaq
- PHVS Nasdaq
- Market Cap
- CLMT 1.2B
- PHVS 1.3B
- IPO Year
- CLMT 2006
- PHVS 2021
- Fundamental
- Price
- CLMT $15.95
- PHVS $23.12
- Analyst Decision
- CLMT Strong Buy
- PHVS Buy
- Analyst Count
- CLMT 6
- PHVS 6
- Target Price
- CLMT $20.38
- PHVS $36.67
- AVG Volume (30 Days)
- CLMT 847.1K
- PHVS 108.1K
- Earning Date
- CLMT 08-08-2025
- PHVS 08-12-2025
- Dividend Yield
- CLMT N/A
- PHVS N/A
- EPS Growth
- CLMT N/A
- PHVS N/A
- EPS
- CLMT N/A
- PHVS N/A
- Revenue
- CLMT $4,070,400,000.00
- PHVS N/A
- Revenue This Year
- CLMT $1.02
- PHVS N/A
- Revenue Next Year
- CLMT $2.01
- PHVS N/A
- P/E Ratio
- CLMT N/A
- PHVS N/A
- Revenue Growth
- CLMT N/A
- PHVS N/A
- 52 Week Low
- CLMT $7.68
- PHVS $11.51
- 52 Week High
- CLMT $25.29
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- CLMT 58.76
- PHVS 60.75
- Support Level
- CLMT $12.94
- PHVS $21.56
- Resistance Level
- CLMT $14.49
- PHVS $24.01
- Average True Range (ATR)
- CLMT 0.90
- PHVS 1.33
- MACD
- CLMT 0.10
- PHVS 0.16
- Stochastic Oscillator
- CLMT 88.53
- PHVS 80.00
About CLMT Calumet Specialty Products Partners L.P. Common Units
Calumet Inc is a producer of specialty products, including base oils, specialty oils, solvents, esters, and waxes, as well as a variety of fuel and fuel-related products, including asphalt and heavy fuel oils. The company manufactures, formulates, and markets a variety of specialty branded products to customers in various consumer-facing and industrial markets. Its segments include: Specialty Products and Solutions; Montana/Renewables; Performance Brands; and Corporate. The company generates maximum revenue from Fuels, asphalt and other by-products.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.